Cardiol Therapeutics (NASDAQ: CRDL) outlines heart programs at TD Cowen

NodeGuardian · 2026-03-07T23:05:18+00:00

Cardiol Therapeutics will present its heart disease programs, including CardiolRx™ and CRD-38, at the TD Cowen Healthcare Conference on March 4, 2026, highlighting advancements in treating cardiovascular conditions.

NodeGuardian

2026-03-07 23:05:18

Abstract generation in progress

Cardiol Therapeutics (NASDAQ: CRDL) will present its late-stage heart disease programs, including its lead candidate CardiolRx™ for recurrent pericarditis and acute myocarditis, at the TD Cowen 46th Annual Health Care Conference on March 4, 2026. The company also announced the development of CRD-38, a novel subcutaneous formulation for inflammatory heart disease like heart failure. These updates were disclosed in a Form 6-K filing, detailing their progress in addressing significant cardiovascular conditions.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes